ArticlePNAS nexus2022
Containing novel SARS-CoV-2 variants at source is possible with high-intensity sequencing.
Article in PNAS nexus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Drivers and impact of the early silent invasion of SARS-CoV-2 Alpha.Nature communications · 2024Article
- Predicting the spread of SARS-CoV-2 variants: An artificial intelligence enabled early detection.PNAS nexus · 2024Article
- Genomic assessment of invasion dynamics of SARS-CoV-2 Omicron BA.1.Science (New York, N.Y.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Throughout the COVID-19 pandemic, control of transmission has been repeatedly thwarted by the emergence of variants of concern (VOC) and their geographic spread. Key questions remain regarding effective means of minimizing the impact of VOC, in particular the feasibility of containing them at source, in light of global interconnectedness. By analysing a stochastic transmission model of COVID-19, we identify the appropriate monitoring requirements that make containment at source feasible. Specifically, precise risk assessment informed primarily by epidemiological indicators (e.g. accumulated hospitalization or mortality reports), is unlikely prior to VOC escape. Consequently, decision makers will need to make containment decisions without confident severity estimates. In contrast, successfully identifying and containing variants via genomic surveillance is realistic, provided sequence processing and dissemination is prompt.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.